Search results
Showing 2951 to 3000 of 4091 results for patient
Awaiting development Reference number: GID-TA11870 Expected publication date: TBC
Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]
Awaiting development Reference number: GID-TA11892 Expected publication date: TBC
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]
Awaiting development Reference number: GID-TA11403 Expected publication date: TBC
Cancer: invasive cancer diagnosed via emergency routes (IND1)
This indicator covers the proportion of invasive cases of cancer diagnosed via an emergency route. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCC01
This indicator covers the percentage of patients who reached 75 years old in the preceding 12 months, who have received a shingles vaccine between the ages of 70 and 75 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM201
Awaiting development Reference number: GID-TA11596 Expected publication date: TBC
Awaiting development Reference number: GID-TA11558 Expected publication date: TBC
Awaiting development Reference number: GID-TA11516 Expected publication date: 06 May 2027
Awaiting development Reference number: GID-TA11594 Expected publication date: TBC
Deucravacitinib for treating active psoriatic arthritis [TSID11981]
Awaiting development Reference number: GID-TA11510 Expected publication date: TBC
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [TSID12015]
Awaiting development Reference number: GID-TA11551 Expected publication date: TBC
Awaiting development Reference number: GID-TA11632 Expected publication date: TBC
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902]
Awaiting development Reference number: GID-TA11417 Expected publication date: TBC
Awaiting development Reference number: GID-TA11549 Expected publication date: TBC
Awaiting development Reference number: GID-TA11507 Expected publication date: TBC
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]
Awaiting development Reference number: GID-TA11383 Expected publication date: TBC
Awaiting development Reference number: GID-TA11608 Expected publication date: TBC
Awaiting development Reference number: GID-TA11575 Expected publication date: TBC
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941
Awaiting development Reference number: GID-TA11481 Expected publication date: TBC
Awaiting development Reference number: GID-TA11845 Expected publication date: TBC
Awaiting development Reference number: GID-TA11880 Expected publication date: TBC
Awaiting development Reference number: GID-TA11882 Expected publication date: TBC
Awaiting development Reference number: GID-TA11885 Expected publication date: TBC
Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]
Awaiting development Reference number: GID-TA11721 Expected publication date: TBC
Awaiting development Reference number: GID-TA11879 Expected publication date: TBC
Awaiting development Reference number: GID-TA11825 Expected publication date: TBC
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]
Awaiting development Reference number: GID-TA11886 Expected publication date: TBC
Awaiting development Reference number: GID-TA11706 Expected publication date: TBC
Awaiting development Reference number: GID-TA11653 Expected publication date: TBC
Awaiting development Reference number: GID-TA11641 Expected publication date: TBC
Cosibelimab for treating advanced cutaneous squamous cell carcinoma [ID6663]
Awaiting development Reference number: GID-TA11883 Expected publication date: TBC
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]
Awaiting development Reference number: GID-TA11881 Expected publication date: TBC
Myocardial infarction: medication for MI in preceding 12 months (IND125)
This indicator covers the percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), dual antiplatelet therapy, a statin and a beta blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM79
Tell us about an interventional procedure you think should be assessed by NICE.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
Workplace health: long-term sickness absence and capability to work (NG146)
This guideline covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence.
In development Reference number: GID-TA11229 Expected publication date: TBC
Awaiting development Reference number: GID-TA11040 Expected publication date: TBC
In development Reference number: GID-TA11803 Expected publication date: TBC
Awaiting development Reference number: GID-TA11534 Expected publication date: TBC
Awaiting development Reference number: GID-TA11161 Expected publication date: TBC
Fenebrutinib for treating relapsing multiple sclerosis [ID6577]
Awaiting development Reference number: GID-TA11775 Expected publication date: TBC
Norucholic acid for treating primary sclerosing cholangitis [ID6583]
Awaiting development Reference number: GID-TA11782 Expected publication date: TBC
Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]
Awaiting development Reference number: GID-TA11744 Expected publication date: TBC
Awaiting development Reference number: GID-TA11743 Expected publication date: TBC
Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]
Awaiting development Reference number: GID-TA11667 Expected publication date: TBC
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]
Awaiting development Reference number: GID-TA11692 Expected publication date: TBC
Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]
Awaiting development Reference number: GID-TA11755 Expected publication date: TBC
Awaiting development Reference number: GID-TA11754 Expected publication date: TBC
LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]
Awaiting development Reference number: GID-TA11741 Expected publication date: TBC